[1]朱佳佳,马东红,刘　云,等.特发性膜性肾病患者足突宽度与尿蛋白量和他克莫司治疗反应的关系[J].新乡医学院学报,2017,34(5):381-384.[doi:10.7683/xxyxyxb.2017.05.009]
　ZHU Jia-jia,MA Dong-hong,LIU Yun,et al.Relationship between the foot process width，urinary protein and the patient′s response to tacrolimus in patients with idiopathic membranous nephropathy[J].Journal of Xinxiang Medical University,2017,34(5):381-384.[doi:10.7683/xxyxyxb.2017.05.009]
点击复制

特发性膜性肾病患者足突宽度与尿蛋白量和他克莫司治疗反应的关系
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
34
期数:
2017年5
页码:
381-384
栏目:
临床研究
出版日期:
2017-05-05

文章信息/Info

Title:
Relationship between the foot process width，urinary protein and the patient′s response to tacrolimus in patients with idiopathic membranous nephropathy
作者:
朱佳佳1; 马东红1; 刘　云1; 许清玉1; 刘向东1; 张连云1; 马海军1; 朱铁锤1; 杨　军1; 侯玉龙1; 段　峥1; 周一龙2; 郭明好2
（1.新乡医学院第一附属医院肾病科，河南　卫辉　453100；2.新乡医学院第三附属医院肾病科，河南　新乡　453003）
Author(s):
ZHU Jia-jia1; MA Dong-hong1; LIU Yun1; XU Qing-yu1; LIU Xiang-dong1; ZHANG Lian-yun1; MA Hai-jun1; ZHU Tie-chui1; YANG Jun1; HOU Yu-long1; DUAN Zheng1; ZHOU Yi-long2; GUO Ming-hao2
（1.Department of Nephrology，the First Affiliated Hospital of Xinxiang Medical University，Weihui 453100，Henan Province，China；2.Department of Nephrology，the Third Affiliated Hospital of Xinxiang Medical University，Xinxiang 453003，Henan Province，China）
关键词:
特发性膜性肾病; 尿蛋白; 足突宽度; 他克莫司
Keywords:
idiopathic membranous nephropathy; urinary protein; foot process width; tacrolimus
分类号:
R692
DOI:
10.7683/xxyxyxb.2017.05.009
文献标志码:
A
摘要:
目的　观察特发性膜性肾病（IMN）患者足突宽度（FPW）与尿蛋白量（Upro）和他克莫司方案治疗反应的关系。方法　选取2015年6月至2016年3月新乡医学院第一附属医院确诊为IMN患者34例，根据患者FPW中位数将患者分为轻度足突融合组（FPW≤2 200 nm）12例和重度足突融合组（FPW>2 200 nm）22例，患者均应用他克莫司方案进行治疗6个月。观察患者FPW与Upro的相关性；不同FPW组患者应用他克莫司治疗后的临床疗效。结果　34例IMN患者平均FPW为（2 579.90±994.50）nm，FPW与Upro存在显著正相关（r=0.607，P<0.001）。轻度足突融合组患者平均FPW为（1 776.30±560.20）nm，24 h Upro为（2.10±0.70）g；重度足突融合组患者FPW为（2 914.80±947.90）nm，24 h Upro为（6.50±2.20）g；重度足突融合组患者FPW和24 h Upro均较高于轻度足突融合组（P<0.05）。治疗后，轻度足突融合组患者12例中完全缓解（CR）4例（33.3%），部分缓解（PR）2例（16.7%），无效（NR）6例（50.0%），治疗总缓解率50.0%（6/12）；重度足突融合组患者22例中CR 7例（32.4%），PR 12例（41.2%），NR 3例（26.5%），治疗总缓解率86.3%（19/22）；重度足突融合组患者治疗总缓解率显著高于轻度足突融合组（χ2=6.801，P<0.05）。结论　足突融合参与尿蛋白的发生，其严重程度决定了Upro的多少；他克莫司对于严重足突融合的患者治疗效果较好，这类患者在治疗方案上应优先选择他克莫司。
Abstract:
Objective　To observe the correlation between the foot process width（FPW），urinary protein（Upro）and the treatment response of patients to tacrolimus in patients with idiopathic membranous nephropathy（IMN）.Methods　Thirty-four patients with IMN were selected in the First Affiliated Hospital of Xinxiang Medical University from June 2015 to March 2016.The patients were divided into mild foot process fusion group（FPW≤2 200 nm）（n=12）and severe foot process fusion group（FPW>2 200 nm）（n=22）according to the median of FPW.All patients were treated with tacrolimus for 6 months.The relationship between the FPW and Upro were observed in all patients；the therapeutic effect of patients in mild foot fusion group and severe foot fusion group were observed.Results　The average FPW of 34 patients was （2 579.90± 994.50）nm.The FPW was positive correlation with Upro（r=0.607，P<0.001）.The average FPW and Upro in 24 h of patients in the mild foot process fusion group was（1 776.30±560.20）nm and （2.10±0.70）g respectively；the average FPW and Upro in 24 h of patients in the severe foot process group was（2 914.80±947.90）nm and （6.50±2.20）g respectively.The average FPW and Upro in 24 h of patients in the severe foot fusion group were significantly higher than those in the mild foot process fusion group（P<0.05）.After treatment，in the mild foot process fusion group，4 patients were complete remission（CR）（33.3%），2 patients were partial remission（PR）（16.7%），6 patients were no response（NR）（50.0%），the total remission rate was 50.0%（6/12）；in the severe foot process group，7 patients were CR（32.4%），12 patients were PR（41.2%），3 patients were NR（26.5%），the total remission rate was 86.3%（19/22）；the remission rate of patients in the severe foot process fusion group was significantly higher than that in the mild foot process fusion group（χ2=6.801，P<0.05）.Conclusion　Foot process fusion participate in the occurrence of Upro，and its severity determines the amount of proteinuria.Tacrolimus has better treatment effect in the patients with severe fusion of foot processes，it should be as the first choice for these patients.

参考文献/References:

［1］　宋爱凤，杨巧芳，沈敬华.足细胞损伤与膜性肾病的研究进展［J］.中国医药科学，2013，3（23）：49-51.
［2］　汪年松，桂定坤，李军辉.他克莫司在肾脏病中的合理应用［J/CD］.中华肾病研究电子杂志，2014，3（4）：200-203.DOI:10.3877/cma.j.issn.2095-3216.2014.04.006.
［3］　管娜，丁洁，王素霞，等.Alport 综合征足突融合与蛋白尿关系探讨 ［G］.中华医学会第五次全国儿科中青年学术交流大会论文汇编（上册），2008.
［4］　李艺，王帅，赵景宏，等.他克莫司与环磷酰胺联合激素治疗特发性膜性肾病的疗效比较［J］.中国临床药理学与治疗学，2012，17（7）：797-801.
［5］　VAN DEN BERG J G，VAN DEN BERGH WEERMAN M A，ASSMANN K J，et al.Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies［J］.Kidney Int，2004，66（5）：1901-1906.
［6］　KALLURI R.Proteinuria with and without renal glomerular podocyte effacement［J］.J Am Soci Nephrol，2006，17（9）：2383-2389.
［7］　张宜苗，初荣，柴立军，等.微小病变肾病患者恢复期足突超微结构的改变［J/CD］.中华临床医师杂志：电子版，2011，5（19）：5674-5679.DOI：10.3877/cma.j.issn.1674-0785.2011.19.027.
［8］　LIU X J，ZHANG Y M，WANG S X，et al.Ultrastructural changes of podocyte foot processes during the remission phase of minimal change disease of human kidney［J］.Nephrology，2014，19（7）：392.
［9］　GLASSOCK R J.Diagnosis and natural course of membranous nephropathy［J］.Semin Nephrol，2003，23（4）：324-332.
［10］　OHSE T，VAUGHAN M R，KOPP J B，et al.De novo expression of podocyte proteins in parietal epithelial cells during experimental glomerular disease［J］.Ajp Renal Physiol，2010，298（3）：702-711.
［11］　DEBIEC H，GUIGONIS V，MOUGENOT B，et al.Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies［J］.New Engl J Med，2002，346（26）：2053-2060.
［12］　BECK JR L H，BONEGIO R G B，LAMBEAU G，et al.M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy［J］.New Engl J Med，2009，361（1）：11-21.
［13］　CYBULSKY A V，WALSH M，KNOLL G，et al.Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis：management of glomerulonephritis in adults［J］.Am J Kidney Dis，2014，63（3）：363-377.
［14］　吴燕，左科，王波，等.激素联合环磷酰胺治疗特发性膜性肾病前瞻性对照性临床观察［J］.肾脏病与透析肾移植杂志，2012，21（2）：109-114.
［15］　陈意志，李平，胡婕，等.新型免疫抑制剂治疗特发性膜性肾病的Meta分析［J/CD］.中华肾病研究电子杂志，2014，3（2）：91-98.DOI:10.3877/cma.j.issn.2095-3216.2014.02.007.
［16］　HE L，PENG Y，LIU H，et al.Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids［J］.J Nephrol，2013，26（3）：564-571.

相似文献/References:

[1]姬　萌,马媛媛,郭醉爽,等.昆仙胶囊与他克莫司治疗特发性膜性肾病疗效比较[J].新乡医学院学报,2021,38(5):472.[doi:10.7683/xxyxyxb.2021.05.016]
　JI Meng,MA Yuanyuan,GUO Zuishuang,et al.Comparison of the effects of Kunxian capsule and tacrolimus in the treatment of idiopathic membranous nephropathy[J].Journal of Xinxiang Medical University,2021,38(5):472.[doi:10.7683/xxyxyxb.2021.05.016]
[2]阎　磊,范晓光,高素华,等.肾组织M-型磷脂酶A2受体抗原阳性的特发性膜性肾病患者临床特征分析[J].新乡医学院学报,2017,34(8):700.[doi:10.7683/xxyxyxb.2017.08.010]
　YAN Lei,FAN Xiao-guang,GAO Su-hua,et al.Clinical features of patients with kidney tissue M-type phospholipase A2 receptor antigen positive idiopathic membranous nephropathy[J].Journal of Xinxiang Medical University,2017,34(5):700.[doi:10.7683/xxyxyxb.2017.08.010]
[3]龚　洵,杨美桃,刘海意,等.子痫前期患者24 h尿蛋白定量与妊娠结局的相关性[J].新乡医学院学报,2017,34(9):808.[doi:10.7683/xxyxyxb.2017.09.007]
　GONG Xun,YANG Mei-tao,LIU Hai-yi,et al.Correlation between 24 h urinary protein quantitation and pregnancy outcome in patients with pre-eclampsia[J].Journal of Xinxiang Medical University,2017,34(5):808.[doi:10.7683/xxyxyxb.2017.09.007]
[4]赵伟河,牛振霞,郎金飞,等.益肾补脾汤治疗糖尿病肾脏病Ⅳ期疗效观察[J].新乡医学院学报,2023,40(4):329.[doi:10.7683/xxyxyxb.2023.04.006]
　ZHAO Weihe,NIU Zhenxia,LANG Jinfei,et al.Clinical efficacy of Yishen Bupi decoction in the treatment of stage IV diabetic kidney disease[J].Journal of Xinxiang Medical University,2023,40(5):329.[doi:10.7683/xxyxyxb.2023.04.006]

更新日期/Last Update: 2017-05-05